Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of alfuzosin prolonged-release 10 mg vs Xatral XL 10 mg under fed conditions in healthy Thai male volunteers
TCTR20201002006Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alfuzosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start May 2021; status: not yet recruiting.
02
Drugs
alfuzosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on TCTR20201002006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201002006.